{
    "id": 31670,
    "fullName": "PIK3CA exon20",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA exon 20 indicates an unspecified mutation has occurred in exon 20 of the PIK3CA gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "exon20",
    "createDate": "11/27/2019",
    "updateDate": "11/27/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19314,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), Afinitor (everolimus) demonstrated greater benefit on progression-free survival in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring PIK3CA exon 9 mutations (HR=0.26) compared to patients harboring PIK3CA exon 20 mutations (HR=0.56) (PMID: 26503204; NCT00863655).",
            "molecularProfile": {
                "id": 34044,
                "profileName": "PIK3CA exon20"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16925,
                    "pubMedId": 26503204,
                    "title": "Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26503204"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34044,
            "profileName": "PIK3CA exon20",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}